Title:Treatment with Cinacalcet in Hemodialysis Patients with Severe Secondary Hyperparathyroidism, Influences Bone Mineral Metabolism and Anemia Parameters
VOLUME: 15 ISSUE: 3
Author(s):Maria Aktsiali, Theodora Papachrysanthou , Ioannis Griveas, Christos Andriopoulos, Panagiotis Sitaras, Ioannis K. Triantafyllopoulos and George I. Lambrou*
Affiliation:Private Dialysis Unit “Nefroiatriki”, Chlois 85 Str., 14452, Metamorfosi, Athens, Private Dialysis Unit “Nefroiatriki”, Chlois 85 Str., 14452, Metamorfosi, Athens, 417 Veterans Army Administration Hospital of Athens, Monis Petraki 10-12, 11521, Athens, Private Dialysis Unit “Nefroiatriki”, Chlois 85 Str., 14452, Metamorfosi, Athens, Private Dialysis Unit “Nefroiatriki”, Chlois 85 Str., 14452, Metamorfosi, Athens, Graduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Mikras Asias 75, 11527, Goudi, Athens, Graduate Program “Metabolic Bones Diseases”, National and Kapodistrian University of Athens, Medical School, Mikras Asias 75, 11527, Goudi, Athens
Keywords:Cinacalcet, renal disease, dialysis, bone mineral metabolism, anemia, hemoglobin.
Abstract:Background: Due to the premium rate of Chronic Kidney Disease, we have increased
our knowledge with respect to diagnosis and treatment of Bone Mineral Disease (BMD) in End-
Stage Renal Disease (ESRD). Currently, various treatment options are available. The medication
used for Secondary Hyper-Parathyroidism gives promising results in the regulation of Ca, P and
Parathormone levels, improving the quality of life. The aim of the present study was to investigate
the relation of cinacalcet administration to not only parathormone, Ca and P but also to anemia
parameters such as hematocrit and hemoglobin.
Materials and Methods: A retrospective observational study was conducted in a Chronic
Hemodialysis Unit. One-hundred ESRD patients were recruited for twenty-four months and were
evaluated on a monthly rate. Biochemical parameters were related to medication prescribed and the
prognostic value was estimated. Cinacalcet was administered to 43 out of 100 patients in a dose of
30-120 mg.
Results: Significant differences were observed in PTH, Ca and P levels with respect to Cinacalcet
administration. Ca levels appeared to be higher at 30mg as compared to 60mg cinacalcet.
Furthermore, a decreasing age-dependent pattern was observed with respect to cinacalcet dosage. A
positive correlation was observed between Dry Weight (DW) and cinacalcet dose. Finally, a
positive correlation between Hematocrit and Hemoglobin and cinacalcet was manifested.
Conclusions: Cinacalcet, is a potential cardiovascular and bone protective agent, which is approved
for use in ESRD patients to assist SHPT. A novel information was obtained from this study,
regarding the improvement of the control of anemia.
